Trial information
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Status: Completed
Protocol number: CAN0010
Company division: Diagnostic
Official Scientific Title: The 'improved management of patients with congestive heart failure in Canada (IMPROVE-CHF CANADA)' study.
Brief summary: This study will evaluate the use of plasma NT-proBNP measurements to improve the diagnostic accuracy of congestive heart failure (CHF) and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement of plasma NT-proBNP.
Study type: Interventional; Randomized; Double Blind; Parallel study
Condition: Congestive Heart Failure
Intervention type: Diagnostic Test
Intervention name: ELECSYS®proBNP
Inclusion criteria:
- adult patients, >=18 years of age;
- presenting to emergency department with shortness of breath, of suspected cardiac etiology.
Exclusion criteria:
- dyspnea clearly not due to CHF;
- acute myocardial infarction;
- advanced renal failure.
Gender: Males or Females
Age limits: Min: 18 Years
Anticipated start date: December, 2004
Trial registration date: 11/23/2006
Date last updated: 11/21/2008
Link to trial result
This trial was conducted at the following locations:
Canada
- Calgary, AB
- Vancouver, BC
- Halifax, NS
- Hamilton, ON
- Toronto, ON
- Montreal, QC
- Quebec, QC
